Day One

• Understanding why pharma would invest. What gap are the innovative technologies filling and what is the sentiment for dealmaking right now?
• What do pharma need to see? Sharing direction into what is expected when approaching pharma as a partner
• Insights into how biotech can differentiate in crowded markets

What is this session?

• With a high concentration of relevant companies in one place, the pharma icebreaker tables offer a guaranteed opportunity for face-to-face interactions. Whether you’re connected on the One-on-One Partnering™ portal or not, this is a formal opportunity to introduce yourself and your organization

How is this organized?

• Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selections to meet with companies they haven’t scheduled meetings with yet
• With these selections, we will build a schedule of company rotations through each pharma’s table, across 90 minutes
• This ensures you meet face-to-face with priority companies and can introduce yourself to new pharma contacts early in the event. Don’t miss out on this unique chance to expand your network and forge valuable connections!

The industry’s favorite partnering portal, search the full attendee list, message and schedule meetings in

calendars ahead of the conference and automatically book private meeting spaces in the room adjacent to the talks.

• Discussing examples of deal evaluation and success, including details of the process
• Sharing how early-stage programs can successfully navigate the “show me data” barrier with pharma, and overcome the activation barrier to licencing technologies between equal sized biotech
• Debating recent regulatory and emerging technology shifts, and how these will shape licensing deals for targeted therapies worldwide

What is this session?

At the intersection of innovative research and business conversations, this forum supports the pitching of biotech pipelines and platforms to pharma and investors.

Who can present?

Private or public biotech, NewCo or those with academic affiliations starting up, this session is reserved for those seeking to out-license or co-develop with pharma or other drug developers.

Presentation Session Full

1.15 Presentation by AP Biosciences

1.30 Presentation by Radiopharm Theranostics

1.45 Presentation by Proxima Bio

2.00 Presentation by AnHorn Medicine

2.00 Presentation by HoneyBear Biosciences

2.15 Presentation by FIMECS

One-to-One meeting schedule reopens to allow private meetings between pharma and biotech to continue.

• Evaluating the value of payloads beyond Tubulin and Topoisomerases and why novel payload approaches will hold potential to overcome drug resistance
• What are the challenges when doing something different and how are we decreasing risk when translating preclinical optimism into clinical success
• Specifically thinking about DACs, what is it about small molecule degraders that lend themselves to making good payloads?
• Discussing the panelists approach to business development. What would a win/win business deal look like that focuses on payloads?

Presentation Session Full

4.00 Presentation by Serendip Innovations

4.15 Presentation by Creasallis

4.30 Presentation by Ajitha Prodrug

4.45 Presentation by A&G Pharmaceutical

“People work with people”. Enjoy an informal networking drinks reception with all attending colleagues to catch up, candidly network, initiate and nurture business relationships built before or during the conference so far.

Available from 5.00 to 6.30 make the most of catching contacts away from the office and capitalize on meeting space adjacent to the networking drinks reception